Role of H₂ receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial.

ABSTRACT:

Background

Coronavirus disease 2019 (COVID-19) is a global pandemic putting the population at a high risk of infection-related health hazards, mortality and a potential failure of proper medical therapies. Therefore, it is necessary to evaluate the potential use of the existing drugs that could be used as options for the medical management of COVID-19 patients.

Aim

To evaluate the role of the H₂ receptor blocker "famotidine" in COVID-19 illness.

Methods

This study was done on seriously ill COVID-19 patients admitted to the intensive care unit (ICU) from different institutes in Bangladesh. Patients were divided into famotidine treatment group "A" (famotidine 40 mg to 60 mg oral formulation every 8 h with other treatment as given), and control group "B" (trea

SUBMITTER: Mohiuddin Chowdhury ATM 

PROVIDER: S-EPMC9403664 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature